$169 Million is the total value of Foresite Capital Management II, LLC's 17 reported holdings in Q1 2015. The portfolio turnover from Q4 2014 to Q1 2015 was 56.5% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ZFGN | Buy | Zafgen, Inc. | $56,497,000 | +266.3% | 3,511,456 | +602.1% | 33.47% | +216.9% |
| OREX | Buy | Orexigen Therapeutics, Inc. | $32,886,000 | +35.1% | 4,200,047 | +4.5% | 19.48% | +16.9% |
| EPZM | Buy | Epizyme, Inc. | $14,175,000 | +272.2% | 754,806 | +274.0% | 8.40% | +222.0% |
| ASPX | Sell | Auspex Pharmaceuticals, Inc. | $7,520,000 | -16.6% | 75,000 | -56.4% | 4.46% | -27.8% |
| RGLS | New | Regulus Therapeutics Inc. | $7,280,000 | – | 429,723 | +100.0% | 4.31% | – |
| AERI | Sell | Aerie Pharmaceuticals, Inc. | $6,583,000 | +2.5% | 210,067 | -4.5% | 3.90% | -11.3% |
| NVET | New | Nexvet Biopharma public limited company | $5,688,000 | – | 708,332 | +100.0% | 3.37% | – |
| JUNO | Juno Therapeutics Inc. | $5,555,000 | +16.2% | 91,575 | 0.0% | 3.29% | +0.5% | |
| QTNT | Sell | Quotient Limited | $5,551,000 | -5.9% | 326,509 | -0.3% | 3.29% | -18.5% |
| SCYX | SCYNEXIS, Inc. | $5,502,000 | -16.8% | 662,945 | 0.0% | 3.26% | -28.0% | |
| BDSI | Buy | BioDelivery Sciences International, Inc. | $4,703,000 | -0.6% | 447,878 | +13.8% | 2.79% | -14.0% |
| Sell | Alder Biopharmaceuticals Inc. | $4,535,000 | -36.4% | 157,131 | -35.9% | 2.69% | -44.9% | |
| AGRX | Sell | Agile Therapeutics, Inc. | $4,257,000 | +29.6% | 459,266 | -14.1% | 2.52% | +12.1% |
| TTOO | Buy | T2 Biosystems, Inc. | $3,616,000 | -17.7% | 233,019 | +2.0% | 2.14% | -28.8% |
| SGMO | New | Sangamo BioSciences, Inc. | $2,587,000 | – | 165,000 | +100.0% | 1.53% | – |
| RXDX | Sell | Ignyta, Inc. | $1,843,000 | -2.2% | 185,220 | -32.6% | 1.09% | -15.3% |
| Exit | Amedica Corporation | $0 | – | -225,000 | -100.0% | -0.12% | – | |
| OREX | Exit | Orexigen Therapeutics, Inc.put | $0 | – | -100,000 | -100.0% | -0.42% | – |
| BDSI | Exit | BioDelivery Sciences International, Inc.put | $0 | – | -100,000 | -100.0% | -0.82% | – |
| OREX | Exit | Orexigen Therapeutics, Inc.call | $0 | – | -251,500 | -100.0% | -1.04% | – |
| BDSI | Exit | BioDelivery Sciences International, Inc.call | $0 | – | -170,000 | -100.0% | -1.40% | – |
| Exit | Bellicum Pharmaceuticals, Inc. | $0 | – | -105,000 | -100.0% | -1.66% | – | |
| Exit | Anacor Pharmaceuticals, Inc. | $0 | – | -106,849 | -100.0% | -2.36% | – | |
| PRQR | Exit | ProQR Therapeutics N.V. | $0 | – | -173,067 | -100.0% | -2.57% | – |
| SAGE | Exit | Sage Therapeutics, Inc. | $0 | – | -144,569 | -100.0% | -3.62% | – |
| UAM | Exit | Universal American Corp. | $0 | – | -3,000,000 | -100.0% | -19.06% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2015-05-05
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Epizyme, Inc. | 29 | Q4 2021 | 11.9% |
| Acceleron Pharma Inc. | 24 | Q3 2021 | 4.8% |
| Aerie Pharmaceuticals, Inc. | 22 | Q1 2020 | 40.3% |
| 10x Genomics, Inc. | 17 | Q3 2023 | 100.0% |
| Aimmune Therapeutics, Inc. | 17 | Q3 2019 | 41.0% |
| Alder BioPharmaceuticals, Inc. | 16 | Q3 2019 | 12.6% |
| Zafgen, Inc. | 12 | Q3 2017 | 33.5% |
| BioDelivery Sciences International, Inc. | 12 | Q1 2019 | 3.2% |
| Insmed Incorporated | 11 | Q1 2020 | 13.8% |
| Adaptimmune Therapeutics PLC | 9 | Q4 2018 | 11.3% |
View Foresite Capital Management II, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2023-11-13 |
| 13F-HR | 2023-08-11 |
| 13F-HR | 2023-05-12 |
| 13F-HR | 2023-02-13 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-12 |
| 13F-HR | 2022-05-13 |
| 13F-HR | 2022-02-11 |
| 13F-HR | 2021-11-12 |
| 13F-HR | 2021-08-16 |
View Foresite Capital Management II, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.